General Director Message





















On behalf of Daiichi Sankyo Vietnam, I would like to convey our sincere appreciations to all of stakeholders for supporting Daiichi Sankyo and our staff in Viet Nam.


Viet Nam is one of the fastest countries to develop medical care by implementing advanced medical services and treatment technology as well as nationwide telehealth system. Therefore, expectations to pharmaceutical industries are rising year by year to full fill unmet medical needs.


Daiichi Sankyo is a global pharmaceutical company with more than 100 years of scientific expertise to discover and develop innovative pharmaceuticals like Levofloxacin, Prasugrel and Edoxaban. In Viet Nam, we had started our business by exporting Transamin® (Tranexamic acid) more than half century ago. From 2013 to 2018, Daiichi Sankyo Biotech cooperated with the Japan International Cooperation Agency (JICA) for technology transfer to produce Measles-Rubella (MR) Vaccine by POLYVAC in Vietnam.


We are very eager to contribute improvement quality of life for Vietnamese people by our new innovative medicine and services. Furthermore, we try to be a medical partner with healthcare professionals by providing scientific and educational information, and supporting medical research and education.


Finally, I highly expect and believe that our challenges will be successful, and we do commit all of our activities will keep high ethical standard.


Thank you again, and I wish you and your family every personal success and happiness.






Yukinori Tominaga

General Director

Daiichi Sankyo Vietnam Co., Ltd.






CSR in Vietnam

Technical Cooperation for MR Vaccine Production in Vietnam

read more ...